Comparison Overview

Pii, A Jabil Company

VS

Hikma Pharmaceuticals

Pii, A Jabil Company

10819 Gilroy Road, Hunt Valley, 21031, US
Last Update: 2025-12-23
View Profile
Between 650 and 699
http://www.pharm-int.com

Pharmaceutics International Inc. (Pii) is a leading Contract Development and Manufacturing Organization (CDMO) that provides comprehensive solutions for aseptic and oral dosage forms. Founded in 1994 by Dr. Syed Abidi, a pioneering formulation scientist, Pii has over 30 years of experience handling complex formulations, potent compounds, and controlled substances. Based in Hunt Valley, MD, Pii’s capabilities include lyophilization, high potency isolation, and robotic filling. Our expert teams ensure the highest quality and safety standards, supporting small to medium-volume projects with scalable solutions and unmatched flexibility. Committed to client-centric drug development, Pii's mission is to enhance quality of life through innovative and high-quality pharmaceuticals. Discover more about our services and how we can support your projects at www.pharm-int.com.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 354
Subsidiaries: 0
12-month incidents
1
Known data breaches
1
Attack type number
1
View Profile

Hikma Pharmaceuticals

1 New Burlington Place, London, W1S 2HR, GB
Last Update: 2025-12-19
Between 750 and 799
http://www.hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 10,222
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/pharmaceutics-international.jpeg
Pii, A Jabil Company
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/hikma-pharmaceuticals.jpeg
Hikma Pharmaceuticals
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Pii, A Jabil Company
100%
Compliance Rate
0/4 Standards Verified
Hikma Pharmaceuticals
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

Pii, A Jabil Company has 8.7% more incidents than the average of same-industry companies with at least one recorded incident.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Hikma Pharmaceuticals in 2025.

Incident History — Pii, A Jabil Company (X = Date, Y = Severity)

Pii, A Jabil Company cyber incidents detection timeline including parent company and subsidiaries

Incident History — Hikma Pharmaceuticals (X = Date, Y = Severity)

Hikma Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/pharmaceutics-international.jpeg
Pii, A Jabil Company
Incidents

Date Detected: 12/2025
Type:Breach
Blog: Blog
https://images.rankiteo.com/companyimages/hikma-pharmaceuticals.jpeg
Hikma Pharmaceuticals
Incidents

No Incident

FAQ

Hikma Pharmaceuticals company demonstrates a stronger AI Cybersecurity Score compared to Pii, A Jabil Company company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Pii, A Jabil Company company has historically faced a number of disclosed cyber incidents, whereas Hikma Pharmaceuticals company has not reported any.

In the current year, Pii, A Jabil Company company has reported more cyber incidents than Hikma Pharmaceuticals company.

Neither Hikma Pharmaceuticals company nor Pii, A Jabil Company company has reported experiencing a ransomware attack publicly.

Pii, A Jabil Company company has disclosed at least one data breach, while the other Hikma Pharmaceuticals company has not reported such incidents publicly.

Neither Hikma Pharmaceuticals company nor Pii, A Jabil Company company has reported experiencing targeted cyberattacks publicly.

Neither Pii, A Jabil Company company nor Hikma Pharmaceuticals company has reported experiencing or disclosing vulnerabilities publicly.

Neither Pii, A Jabil Company nor Hikma Pharmaceuticals holds any compliance certifications.

Neither company holds any compliance certifications.

Neither Pii, A Jabil Company company nor Hikma Pharmaceuticals company has publicly disclosed detailed information about the number of their subsidiaries.

Hikma Pharmaceuticals company employs more people globally than Pii, A Jabil Company company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Pii, A Jabil Company nor Hikma Pharmaceuticals holds SOC 2 Type 1 certification.

Neither Pii, A Jabil Company nor Hikma Pharmaceuticals holds SOC 2 Type 2 certification.

Neither Pii, A Jabil Company nor Hikma Pharmaceuticals holds ISO 27001 certification.

Neither Pii, A Jabil Company nor Hikma Pharmaceuticals holds PCI DSS certification.

Neither Pii, A Jabil Company nor Hikma Pharmaceuticals holds HIPAA certification.

Neither Pii, A Jabil Company nor Hikma Pharmaceuticals holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

Marshmallow is a lightweight library for converting complex objects to and from simple Python datatypes. In versions from 3.0.0rc1 to before 3.26.2 and from 4.0.0 to before 4.1.2, Schema.load(data, many=True) is vulnerable to denial of service attacks. A moderately sized request can consume a disproportionate amount of CPU time. This issue has been patched in version 3.26.2 and 4.1.2.

Published
Date
2025-12-22
Updated
Date
2025-12-22
Risk Information
cvss3
Base: 5.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:L
References
Description

KEDA is a Kubernetes-based Event Driven Autoscaling component. Prior to versions 2.17.3 and 2.18.3, an Arbitrary File Read vulnerability has been identified in KEDA, potentially affecting any KEDA resource that uses TriggerAuthentication to configure HashiCorp Vault authentication. The vulnerability stems from an incorrect or insufficient path validation when loading the Service Account Token specified in spec.hashiCorpVault.credential.serviceAccount. An attacker with permissions to create or modify a TriggerAuthentication resource can exfiltrate the content of any file from the node's filesystem (where the KEDA pod resides) by directing the file's content to a server under their control, as part of the Vault authentication request. The potential impact includes the exfiltration of sensitive system information, such as secrets, keys, or the content of files like /etc/passwd. This issue has been patched in versions 2.17.3 and 2.18.3.

Published
Date
2025-12-22
Updated
Date
2025-12-22
Risk Information
cvss4
Base: 8.2
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:H/VI:N/VA:N/SC:H/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

Fedify is a TypeScript library for building federated server apps powered by ActivityPub. Prior to versions 1.6.13, 1.7.14, 1.8.15, and 1.9.2, a Regular Expression Denial of Service (ReDoS) vulnerability exists in Fedify's document loader. The HTML parsing regex at packages/fedify/src/runtime/docloader.ts:259 contains nested quantifiers that cause catastrophic backtracking when processing maliciously crafted HTML responses. This issue has been patched in versions 1.6.13, 1.7.14, 1.8.15, and 1.9.2.

Published
Date
2025-12-22
Updated
Date
2025-12-22
Risk Information
cvss3
Base: 7.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H
References
Description

Authenticated Remote Code Execution (RCE) in PluXml CMS 5.8.22 allows an attacker with administrator panel access to inject a malicious PHP webshell into a theme file (e.g., home.php).

Published
Date
2025-12-22
Updated
Date
2025-12-22
Risk Information
cvss3
Base: 6.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:H/I:H/A:N
References
Description

An issue was discovered in Xiongmai XM530 IP cameras on firmware V5.00.R02.000807D8.10010.346624.S.ONVIF 21.06. The GetStreamUri exposes RTSP URIs containing hardcoded credentials enabling direct unauthorized video stream access.

Published
Date
2025-12-22
Updated
Date
2025-12-22
Risk Information
cvss3
Base: 7.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N
References